Fallopian tube correlates of ovarian serous borderline tumors

American Journal of Surgical Pathology

Volumn 35, Issue 12, 2011, Pages 1759-1765

  Laury, Anna R ^a   Ning, Gang ^b   Quick, Charles M ^a   Bijron, Jonathan ^a   Parast, Mana M ^c   Betensky, Rebeca A ^d   Vargas, Sara O ^e   McKeon, Frank D ^b,f   Xian, Wa ^a,f   Nucci, Marisa R ^a   Crum, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f AGENCY FOR SCIENCE   (Singapore)

Author keywords

fallopian tube; ovarian neoplasms; PAX2; serous borderline tumor

Indexed keywords

PAX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR PAX2;

ADULT; ARTICLE; BIOSYNTHESIS; CHILD; CYSTADENOCARCINOMA; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; OVARY TUMOR; PATHOLOGY; UTERINE TUBE TUMOR;

ADULT; CHILD; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PAX2 TRANSCRIPTION FACTOR;

EID: 81355132228     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318233b0f7     Document Type: Article

References (25)

1. Auersperg N. The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol. 2011;30:12-21.
2. Chen EY, Mehra K, Mehrad M, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol. 2010;222:110-116.
3. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001; 25:1283-1289. (Pubitemid 32917122)
4. Comer MT, Leese HJ, Southgate J. Induction of a differentiated ciliated cell phenotype in primary cultures of Fallopian tube epithelium. Hum Reprod. 1998;13:3114-3120. (Pubitemid 28521861)
5. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology. 2001;38:87-95. (Pubitemid 32193623)
6. Gerstenblith MR, Goldstein AM, Tucker MA. Hereditary genodermatoses with cancer predisposition. Hematol Oncol Clin North Am. 2010;24:885-906.
7. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169. (Pubitemid 46175016)
8. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-443.
9. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal oviduct. J Pathol. 2006;211:26-35. (Pubitemid 46092026)
10. Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 2009;3:97-137.
11. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11:6116-6126. (Pubitemid 41262937)
12. Mulligan RM. A survey of epithelial inclusions in the ovarian cortex of 470 patients. J Surg Oncol. 1976;8:61-66.
13. Norquist BM, Garcia RL, Allison KH, et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer. 2010;116:5261-5271.
14. Okamura H, Katabuchi H. Detailed morphology of human ovarian surface epithelium focusing on its metaplastic and neoplastic capability. Ital J Anat Embryol. 2001;106(2 Suppl 2):263-276.
15. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456. (Pubitemid 33069670)
16. Robey SR, Silva EG. Epithelial hyperplasia of the fallopian tube. Int J Gynecol Pathol. 1990;9:382-383.
17. Roh MH, Yassin Y, Miron A, et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol. 2010;23:1316-1324.
18. Roncucci L, Stamp D, Medline A, et al. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol. 1991;22:287-294.
19. Sakurai J, Hattori N, Nakajima M, et al. Differential expression of the glycosylated forms of MUC1 during lung development. Eur J Histochem. 2007;51:95-102. (Pubitemid 351480292)
20. Saran A. Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling. Future Oncol. 2010;6:1003-1014.
21. Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl. 1995;23:208-218. (Pubitemid 26032877)
22. Sieben NL, Roemen GM, Oosting J, et al. Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants. J Pathol. 2006;210:405-411. (Pubitemid 44830600)
23. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mü llerian system origin? Mod Pathol. 2007;20:856-863. (Pubitemid 47077268)
24. Xian W, Miron A, Roh M, et al. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol. 2010;220:17-23.
25. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404:99-103. (Pubitemid 30143141)